A new vaccine allows pneumonia-causing bacteria to colonize inside the body, springing into action only if the bacteria pose a threat.
The breakthrough approach, coupled with the protein-based vaccine’s potential to counteract more than 90 strains of the bacteria, has the makings to override how vaccines have worked (destroying bacteria before colonization) since the days of Louis Pasteur.
Moreover, it offers what could be the most direct and broad response to pneumonia – the leading cause of death of children worldwide under the age of 5, according to the World Health Organization – as well as meningitis, sepsis and other serious infections caused by Streptococcus pneumoniae, a bacteria more commonly known as pneumococcus.
“These are very serious illnesses that we haven’t been able to completely suppress. The vaccine we’re developing could finally get that job done,” says Blaine A. Pfeifer, PhD, an associate professor of chemical and biological engineering at the University at Buffalo School of Engineering and Applied Sciences.
The work is described in a study, published today (June 6) in the Proceedings of the National Academy of Sciences, led by Pfeifer and UB alumnus Charles H. Jones, PhD, who is leading efforts to commercialize the vaccine at Buffalo-based startup Abcombi Biosciences.
“With conventional vaccines, the approach has been: ‘What bacteria do we want to target and how,’” says Jones, CEO and founder of Abcombi, and a former student of Pfeifer’s. “Our strategy is to shift the paradigm to which diseases do we want to prevent.”
Bacteria is still deadly
To treat and prevent illnesses caused by pneumococcus, doctors almost exclusively relied on penicillin and other common antibiotics. While still used, the effectiveness of these drugs has been waning for decades due to bacteria developing antibiotic resistance.
The situation led pharmaceutical companies to develop preventative vaccines, which have reduced deaths and illnesses, especially in developed nations. But pneumococcus remains a serious problem.
Pneumonia killed 1.3 million people worldwide in 2011, with the majority of deaths in Sub-Saharan Africa and South Asia. In the United States alone, pneumonia, meningitis and sepsis cause tens of thousands of deaths each year, according to the National Foundation for Infectious Diseases.
One reason for this is that current vaccines target only a small percentage – those known to cause the most severe infections – of the more than 90 strains of pneumococcus. These vaccines, which identify pneumococcus by a sugar coating that surround the bacteria, are 56 to 88 percent effective.
A new type of vaccine
The UB and Abcombi-led team took a different approach. Its vaccine identifies strains by proteins attached to the surface of pneumococcus. Laboratory tests show the vaccine can defend against more than 12 strains and that it’s 100 percent effective at promoting the appropriate immune response.
Computer simulations indicate the vaccine would be effective against all strains but additional tests are needed to confirm that.
“It’s like the arcade game Whac-A-Mole. Think of the mallet as a traditional vaccine. It can’t stop all the moles, or in our case, all the strains of bacteria at once,” Jones says. “But our vaccine does just that. It’s like a mallet with 90 heads that strikes all the moles simultaneously.”
The ability to fight numerous strains is important, Jones says, because developing new versions of existing vaccines is both costly and time-consuming.
The new vaccine also differs from what’s on the market by its response to the bacteria.
Current vaccines teach the immune system to indiscriminately destroy bacteria and other pathogens, thus preventing colonization. The approach works, but there is growing concern that it can create space within the body for new and potentially more harmful alternatives to establish residence – similar to antibiotic resistance resulting in new and more potent pathogens.
The new vaccine allows bacteria to exist as long as it causes no harm to body. It instructs the immune system to attack only when the surface proteins, mentioned above, break free of the bacterial coating.
“That’s the signal that this bacteria is becoming a troublemaker, that’s its threatening the body and that it’s necessary to fight back,” Pfeifer says.
Having proved the vaccine’s effectiveness in animals, Abcombi is now leading efforts to conduct human trials.
The Latest on: New vaccine
via Google News
The Latest on: New vaccine
- Is A Measles Vaccine Good For Life? Here's How To Know If You're Protected on April 17, 2019 at 10:56 am
New York Mayor Bill de Blasio, for instance, declared a public health emergency on April 9, requiring people in some zip codes to get the vaccine or pay a fine of up to $1,000. But how do you know if ... […]
- $12 million grant renewal for flu vaccine research on April 17, 2019 at 10:18 am
new ideas and new ways to improve an influenza vaccine that “is so ineffective in many people, especially the elderly, that it is one the top priorities for improvement.” Much of the work is being ... […]
- New recommendations for measles vaccine — for adults on April 17, 2019 at 10:03 am
CHICAGO — With the measles spreading in the largest outbreak in years, are you protected? Even those who got a vaccine, if you are a certain age, you may need another shot. And some never got a ... […]
- Your Health: Although first measles vaccine was named after him he didn't vaccinate his son on April 17, 2019 at 8:55 am
Doctors created the measles vaccine after swabbing his throat when he was sick and isolating the virus cultures for the first time. They called the new vaccine the Edmonston strain, and it helped ... […]
- Officials announce new measures to fight New York measles outbreak on April 17, 2019 at 8:39 am
The order, issued by Rockland County, comes one day after New York City closed a preschool over non-compliance with measles vaccine requirements. Both the county and city are struggling to contain a ... […]
- Measles outbreak fuels interest in eliminating religion as reason to avoid vaccines in N.J. on April 17, 2019 at 8:23 am
With 13 reported measles cases in the state and a massive outbreak in New York, two New Jersey state senators say ... “As a mom and a grandmother and somebody who grew up in era of the polio vaccine I ... […]
- AJC Deja News: Atlanta parents eagerly OK polio vaccines (1955) on April 17, 2019 at 8:04 am
They swamped Georgia health clinic phone lines trying to learn as much as possible about the new vaccine developed by Dr. Jonas Salk, a young medical researcher, offering the best chance to date ... […]
- The case for vaccines on April 17, 2019 at 7:40 am
With science leading the way to a really brave new world the question is not should vaccines be used, but rather how many diseases can be eradicated and lives saved by using them. For those opposed I ... […]
- New York City Being Sued For Making Vaccine Mandatory on April 16, 2019 at 3:38 pm
5 Brooklyn mothers, identified by using only initials, have filed a lawsuit against New York City saying the arbitrary state of emergency order and threat of $1000.00 fine or 6 months in jail is ... […]
- NY measles 2019: Parents sue New York City Department of Health to halt vaccine mandate on April 16, 2019 at 9:07 am
WHITE PLAINS, N.Y. – Parents of New York City children who have not been vaccinated against measles have filed a lawsuit seeking to halt an emergency order requiring vaccinations. The lawsuit stems ... […]
via Bing News